Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing